FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078746475> ?p ?o ?g. }

• W2078746475 endingPage "73" @default.
• W2078746475 startingPage "73" @default.
• W2078746475 abstract "Worldwide, colorectal cancer (CRC) is the fourth most commonly diagnosed malignant disease and the second leading cause of cancer-related death in Western nations. In 2008 there were an estimated 148,810 new cases and 49,960 deaths in the US. For several years different chemotherapeutic regimens, based on fluoropyrimidines, irinotecan and oxaliplatin, have been used in advanced CRC, but survival is still unsatisfactory. New targeted therapies, including drugs and monoclonal antibodies (MoABs), show great promise in the fight against CRC and have shown activity in different disease settings. Cetuximab, a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer (mCRC). As an IgG1 antibody, cetuximab may exert its antitumor efficacy through both EGFR antagonism and antibody-dependent cell-mediated cytotoxicity. The combination of this drug with classical chemotherapies has shown better clinical profiles reflected in an improvement in overall and progression-free survival. Clinical trials established the role of cetuximab, particularly with irinotecan, in irinotecan-refractory/heavily pretreated patients. Whereas cetuximab has a clear indication in the salvage setting, its role in first-line therapy remains investigational. It is particularly encouraging that cetuximab may enhance curative opportunities in patients with early metastatic disease, suggesting that adding cetuximab in first-line therapy may downstage disease in some patients, and, as a result, allow potentially curative resection of previously unresectable metastases. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit, and the role of cetuximab in first-line treatment of metastatic CRC." @default.
• W2078746475 created "2016-06-24" @default.
• W2078746475 creator A5025063054 @default.
• W2078746475 creator A5048244344 @default.
• W2078746475 creator A5059367989 @default.
• W2078746475 creator A5075514238 @default.
• W2078746475 date "2009-04-01" @default.
• W2078746475 modified "2023-09-29" @default.
• W2078746475 title "First-line targeted therapies in the treatment of metastatic colorectal cancer &ndash; role of cetuximab" @default.
• W2078746475 cites W1847661643 @default.
• W2078746475 cites W1874410314 @default.
• W2078746475 cites W1941365207 @default.
• W2078746475 cites W1945415917 @default.
• W2078746475 cites W1952393227 @default.
• W2078746475 cites W1968151389 @default.
• W2078746475 cites W1983104536 @default.
• W2078746475 cites W1995242599 @default.
• W2078746475 cites W1999250974 @default.
• W2078746475 cites W2004445514 @default.
• W2078746475 cites W2008803651 @default.
• W2078746475 cites W2020359797 @default.
• W2078746475 cites W2038882649 @default.
• W2078746475 cites W2051120695 @default.
• W2078746475 cites W2054614254 @default.
• W2078746475 cites W2064047613 @default.
• W2078746475 cites W2068125497 @default.
• W2078746475 cites W2080267208 @default.
• W2078746475 cites W2097644228 @default.
• W2078746475 cites W2098223440 @default.
• W2078746475 cites W2099462532 @default.
• W2078746475 cites W2106656437 @default.
• W2078746475 cites W2110097275 @default.
• W2078746475 cites W2110920272 @default.
• W2078746475 cites W2116150263 @default.
• W2078746475 cites W2128447158 @default.
• W2078746475 cites W2132291471 @default.
• W2078746475 cites W2133399075 @default.
• W2078746475 cites W2134920919 @default.
• W2078746475 cites W2136055188 @default.
• W2078746475 cites W2139119404 @default.
• W2078746475 cites W2142564546 @default.
• W2078746475 cites W2145607335 @default.
• W2078746475 cites W2157416388 @default.
• W2078746475 cites W2158863975 @default.
• W2078746475 cites W2161563098 @default.
• W2078746475 cites W2162313061 @default.
• W2078746475 cites W2163355101 @default.
• W2078746475 cites W2164194457 @default.
• W2078746475 cites W2164837623 @default.
• W2078746475 cites W2167241562 @default.
• W2078746475 cites W2168377135 @default.
• W2078746475 cites W2170517479 @default.
• W2078746475 cites W2227477053 @default.
• W2078746475 cites W2241502530 @default.
• W2078746475 cites W2243460469 @default.
• W2078746475 cites W2264142765 @default.
• W2078746475 cites W2274948752 @default.
• W2078746475 cites W2314927739 @default.
• W2078746475 cites W2333251263 @default.
• W2078746475 cites W2590983108 @default.
• W2078746475 cites W2603539516 @default.
• W2078746475 cites W2964836197 @default.
• W2078746475 cites W2973265150 @default.
• W2078746475 cites W57491703 @default.
• W2078746475 cites W1570334509 @default.
• W2078746475 cites W2115790682 @default.
• W2078746475 doi "https://doi.org/10.2147/ott.s3465" @default.
• W2078746475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2886322" @default.
• W2078746475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20616896" @default.
• W2078746475 hasPublicationYear "2009" @default.
• W2078746475 type Work @default.
• W2078746475 sameAs 2078746475 @default.
• W2078746475 citedByCount "2" @default.
• W2078746475 countsByYear W20787464752014 @default.
• W2078746475 countsByYear W20787464752020 @default.
• W2078746475 crossrefType "journal-article" @default.
• W2078746475 hasAuthorship W2078746475A5025063054 @default.
• W2078746475 hasAuthorship W2078746475A5048244344 @default.
• W2078746475 hasAuthorship W2078746475A5059367989 @default.
• W2078746475 hasAuthorship W2078746475A5075514238 @default.
• W2078746475 hasBestOaLocation W20787464751 @default.
• W2078746475 hasConcept C121608353 @default.
• W2078746475 hasConcept C126322002 @default.
• W2078746475 hasConcept C143998085 @default.
• W2078746475 hasConcept C159654299 @default.
• W2078746475 hasConcept C203014093 @default.
• W2078746475 hasConcept C2778332735 @default.
• W2078746475 hasConcept C2779438470 @default.
• W2078746475 hasConcept C2779998722 @default.
• W2078746475 hasConcept C2780259306 @default.
• W2078746475 hasConcept C2780962732 @default.
• W2078746475 hasConcept C2781187634 @default.
• W2078746475 hasConcept C526805850 @default.
• W2078746475 hasConcept C535046627 @default.
• W2078746475 hasConcept C542903549 @default.
• W2078746475 hasConcept C71924100 @default.
• W2078746475 hasConceptScore W2078746475C121608353 @default.
• W2078746475 hasConceptScore W2078746475C126322002 @default.

• next